Skip to main content

Table 1 Baseline sample characteristics

From: A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study

Variable

Total (n = 60)

Li/VPA (n = 33)

Li/CBZ (n = 27)

P value

Female, n (%)

40 (66.7%)

26 (78.8%)

14 (51.8%)

0.05 *

Age, mean (standard deviation (SD), range)

27.8 (5.1, 18–35)

27.5 (4.7, 18–35)

28.3 (5.7, 18–33)

0.57 **

Age at illness onset, mean (SD, range)

20.4 (6.9, 5–35)

20.0 (7.1, 5–30)

20.9 (6.7, 13–5)

0.72 **

Weight in kg, mean (SD)

71.3 (14.4)

73.2 (14.1))

 

0.09 *

Current mood, n (%)

 Depression

27 (45.0%)

13 (39.4%)

14 (51.9%)

0.57 **

 Mania/hypomania

17 (28.3%)

11 (33.3%)

6 (22.2%)

 

 Mixed state

16 (26.7%)

9 (27.3%)

7 (25.9%)

 

Clinical Global Impressions Scale modified for use in BP, mean (SD, range)

 Overall

3.8 (1.1, 1.0–6.0)

3.8 (1.1, 2.0–6.0)

3.8 (1.0, 1.0–6.0)

0.84 **

 Depression

3.3 (1.6, 0.0–6.0)

3.2 (1.5, 0.0–6.0)

3.4 (1.8, 0.0–6.0)

0.62 **

 Mania/hypomania

2.8 (1.6, 1.0–6.0)

3.2 (1.7, 1.0–6.0)

2.4 (1.3, 1.0–5.0)

0.07 **

Manic symptoms (Young Mania Rating Scale) scores, mean (SD, range)

20.4 (7.2) (5.0–39.0)

19.3 (7.1, 8.0–35.0)

21.6 (7.3, 5.0–39.0)

0.22 **

Depressive symptoms (Hamilton Depression Rating Scale), mean (SD, range)

11.3 (5.9, 2.0–28.0)

11.5 (6.0, 2.0–24.0)

11.1 (5.9, 4.0–28.0)

0.81 **

  1. Li/VPA: lithium plus valproic acid group
  2. Li/CBZ: lithium plus carbamazepine group
  3. *Determined by the Fisher exact test.
  4. **Determined by the student t test.